Company intelligence / Profile preview

GES Group

Spain

Ownership: Private
Development stage: Other

Overview

GES Group was a leading Spanish specialty pharmaceutical company focused on developing, manufacturing, and marketing injectable drugs, primarily in the pain and anti-infective segments. It operated internationally and was acquired by Altan Pharma in 2015, marking the end of its independent operations.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: Small moleculeInjectable
Industry: Biotech

Beyond the preview

Go deeper on GES Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GES Group.

Explore the full profile